Objective: To assess the efficacy of conservative chemotherapy for inoperable desmoid tumor(DT) and analyze the prognostic factors.Methods:From November 2008 to April 2016,71 patients of inoperable DT were treated with vinorelbine and low-dose methotrexate in the Department of Bone and Soft Tissue Tumors,Peking University Cancer Hospital&Institute,and enrolled in this retrospective study.The chemotherapy duration is one year.The efficacy of chemotherapy and the prognosis were observed.Results:Of the 71 patients,55% were female.Age of onset varied from 1 to 47 years,and the median age was 14years.Only 11(15.5%)cases suffered primary tumor.The distribution of the site of tumors was:31(43.7%)in the trunk,36(50.7%)in the limbs,and 4(5.6%)in the peritoneal and pelvic cavity.The size of tumor(the maximum diameter)differed from 2 to 37 cm with a mean of 9.3 cm.The median follow-up duration was 28(range,6–87)months.Common side effects included:nausea and vomiting,liver injury,bone marrow suppression and oral ulcers.When the chemotherapy finished,1(1.4%)case achieved complete response,24(33.8%)achieved partial response,37(52.1%)achieved stable disease and 9(12.7%)had progressive disease.The overall response rate was 87.3%.The progression-free survival(PFS)of the participants were from 6 to 87 months,and the 2-,3-and 5-year PFS was 79.9%,68.4% and 36.3%,respectively.No significant difference was identified in PFS in subgroups of gender,age of onset,age of chemotherapy,tumor site and tumor size.Conclusions:For recurrent,inoperable and progressive DT,enough course of chemotherapy with vinorelbine combined with low-dose methotrexate was an optional choice for local control. Objective: To assess the efficacy of conservative chemotherapy for inoperable desmoid tumor (DT) and analyze the prognostic factors. Methods: From November 2008 to April 2016, 71 patients of inoperable DT were treated with vinorelbine and low-dose methotrexate in the Department of Bone and Soft Tissue Tumors, Peking University Cancer Hospital & Institute, and enrolled in this retrospective study. The chemotherapy duration is one year. The efficacy of chemotherapy and the prognosis were observed. Results: Of the 71 patients, 55% were female. Age of forientned From 1 to 47 years, and the median age was 14 years. Of 11 (15.5%) cases suffered primary tumors. The distribution of the site of tumors was: 31 (43.7%) in the trunk, 36 (50.7%) in the limbs , and 4 (5.6%) in the peritoneal and pelvic cavity. The size of the tumor (the maximum diameter) differed from 2 to 37 cm with a mean of 9.3 cm.The median follow-up duration was 28 (range, 6-87 ) months. Common side effects included: nausea and vomiting, liver injury, bone marrow sup (1.4%) achieved achieved response, 24 (33.8%) achieved partial response, 37 (52.1%) achieved stable disease and 9 (12.7%) had progressive disease. rate was 87.3% .The progression-free survival (PFS) of the participants were from 6 to 87 months, and the 2-, 3-and 5-year PFS was 79.9%, 68.4% and 36.3%, respectively. No significant difference was identified in PFS in subgroups of gender, age of onset, age of chemotherapy, tumor site and tumor size. Conclusions: For recurrent, inoperable and progressive DT, enough course of chemotherapy with vinorelbine combined with low-dose methotrexate was an optional choice for local control.